STOK — Stoke Therapeutics
Median target
$40
calls from the last 12 months
Implied return
+48.2%
median target vs. price
Coverage
10 analysts · 10 calls
updated in the last 12 months
Consensus
10/0/0+10 net
Buy / Hold / Sell
Which analysts are behind STOK's consensus?
See every current rating, price target and the analysts' track records for Stoke Therapeutics — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 10 analysts with calls on STOK updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
STOK elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-11-02 | Insiders | Ticho BarryCHIEF MEDICAL OFFICER | Insider sale | 7.0K sh @ $26.38 · planned trade | $185K |
| 2026-11-02 | Insiders | Ticho BarryCHIEF MEDICAL OFFICER | Insider sale | 200 sh @ $26.99 · planned trade | $5K |
| 2026-10-21 | Insiders | Edward Kaye | Proposed sale | 1.5M units · 2.32% of shares outstanding | $38.4M |
| 2026-10-02 | Insiders | Allan JonathanGENERAL COUNSEL & CORP S | Insider sale | 627 sh @ $26.33 · planned trade | $17K |
| 2026-10-01 | Insiders | Ticho BarryCHIEF MEDICAL OFFICER | Insider sale | 1.1K sh @ $26.16 · planned trade | $27K |
More: insider activity · executive branch · trending